Navigation Links
Specialty Blades, Inc. Announces Letter of Intent to Acquire Popper and Sons
Date:9/17/2007

Combined Company to Provide Expanded Solutions to Medical Device and Diagnostics Industries

STAUNTON, Va., Sept. 17 /PRNewswire/ -- Specialty Blades, Inc. (SBI) announced today that it has entered into a Letter of Intent to purchase Popper and Sons, Inc. (Popper). Popper supplies a variety of specialty needle and tubing products to the medical device and diagnostics industries. The combination will create the world's leading cutting and piercing component company serving the medical device industry with estimated combined sales of $35M. Terms of the transaction were not disclosed.

"Popper's portfolio of specialty needle and tubular products complements our current medical device contract manufacturing strategy," said Peter Harris, President and CEO of SBI. "The combined offerings should give medical device and diagnostics companies the broadest array of cutting and piercing device development and production skills in the industry and further cement our position as the cutting and piercing center of excellence for these markets. The transaction is also expected to substantially increase our revenues and is an important step in our strategy to grow our business and increase shareholder value," added Mr. Harris.

According to Joseph Popper, President of Popper, "Medical contract manufacturers need to broaden the array of solutions provided to the device industry. The combined capabilities of the two companies will create an offering unlike any other, helping device developers to create higher performing products and improving outcomes for patients." Information about Popper and its offerings is available at http://www.popperandsons.com.

The acquisition, which is subject to customary conditions, is expected to close on or before December 31st, 2007.


'/>"/>
SOURCE Standard Blades, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. All Specialty Care Treatments Will Be Offered At Belle Vue.
2. Inhospitable Response Curtail Growth Of Specialty Hospitals: United States
3. Apollo to Open Super-specialty Hospital in Oman by Year-end
4. Envisaged Specialty Training Programme For Junior Doctors Encounters a Speed Breaker
5. Reliance Group to Develop Specialty Blood Products
6. Vasan Group to Open Eight Specialty Eye Hospitals
7. Early Prostate Cancer: Specialty of Physician Influences Type of Therapy Received
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... , ... September 20, 2017 , ... Doctors on Liens ... their qualified network of medical professionals working on a personal injury lien basis. Founded ... Surgery Inc brings these esteemed doctors’ vast experience with orthopedic injuries to patients in ...
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer True ... edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes Convention ... speakers — representing such thought-leading companies as JP Morgan Chase, GE Digital, ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is proud ... The Guard®, has helped another long-time client pass their Department of Health and ... the law. , Thanks to the help of the Compliancy Group's Audit Response ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... social campaign, “Humans With Vaginas.” The goal is to ignite conversation via social ... personal care products. The brand has declared September “Humans with Vaginas” month, releasing ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t ... risk of price gouging for their prescription drugs, according to a new comparison ... isn’t negotiating on our behalf, there’s no consistency in drug pricing among drug ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)...  Just 18 months after its February 2016 launch, ... the appointment of three new senior people to its ... Jones-Phillips and James Wright bring decades ... Tammy Wynne joins as Director, ... She has over ten years, experience in global market ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology: